Is There an Alternative to Alternating Adjuvant Therapy for Breast Cancer?

References

• Carter C, Allen C, Henson D. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63: 181–187
   PubMed Web of Science ®Google Scholar
• Fisher B, Redmond C, Poisson R. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of beast cancer. N Engl J Med 1989; 320: 822–828
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trailists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 339: 1–15; 71–85
   PubMed Web of Science ®Google Scholar
• Skipper HE, Schabel FM, Jr, Wilcox WS. Experimental evaluation of potential anticancer agents XIII: On the criteria and kinetics associated with “curability” of experimental leukemia. Cancer Chemother Rep 1964; 35: 1–111
   PubMedGoogle Scholar
• Skipper HE. Laboratory models: The historical perspective. Cancer Treat Rep 1986; 70: 3–7
   PubMedGoogle Scholar
• DeVita VT. Principles of chemotherapy. Cancer: Principles and Practice, 3rd ed, VT DeVita, S Hellman, SA Rosenberg. JB Lippincott, Philadelphia 1988; 279
   Google Scholar
• Dolnick BJ, Berenson RJ. Correlation of dihydrofolate reductase elevation with gene amplification in a homogeneously staining chromosomal region in L5178Y cells. J Cell Biol 1979; 83: 399–402
   Google Scholar
• Goldstein LJ, Galski H. Expression of multidrug resistance gene in human tumors. J Natl Cancer Inst 1989; 81: 116–124
   PubMed Web of Science ®Google Scholar
• Luria SE, Delbruck M. Mutations of bacteria from virus sensitivity to virus resistance. Genetics 1943; 28: 491
   PubMedGoogle Scholar
• Law LW. Origin of resistance of leukaemic cells to folic acid antagonists. Nature 1952; 169: 628–629
   PubMed Web of Science ®Google Scholar
• DeVita VT, Young RC, Canellos GP. Combination vs. single agent chemotherapy: A review of the basis for selection of drug treatment of cancer. Cancer 1975; 35: 98–110
   PubMed Web of Science ®Google Scholar
• Goldie JH, Coldman AJ. A mathematic model for relating drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727–1733
   PubMedGoogle Scholar
• Goldie JH. Scientific basis for adjuvant and primary (neoadjuvant) chemotherapy. Semin Oncol 1987; 14: 1–7
   PubMed Web of Science ®Google Scholar
• Coldman AJ, Goldie JH. A mathematical model of drug resistance in neoplasms. Drug and Hormone Resistance in Neoplasia, Vol 1, N Bruchovsky, JH Goldie. FL CRC Press, Boca Raton 1982; 55–78
   Google Scholar
• Day R. Treatment sequencing, asymmetry, and uncertainty: Protocol strategies for combination chemotherapy. Cancer Res 1986; 46: 3876–3885
   PubMed Web of Science ®Google Scholar
• Ludwig Breast Cancer Study Group. Combination adjuvant chemotherapy for node-positive breast cancer. N Engl J Med 1988; 319: 677–683
   PubMed Web of Science ®Google Scholar
• Perloff M, Norton L, Korzun AH. Advantage of an Adriamycin combination plus halotestin after initial cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone for adjuvant therapy of node-positive breast cancer. Proc Am Soc Clin Oncol 1986; 5: 70
   Google Scholar
• Kardinal CG, Perry MC, Korzun AH. Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy: A subset analysis of CALGB study 8081. Cancer 1988; 61: 415–519
   PubMed Web of Science ®Google Scholar
• Valagussa P, Tancini G, Bonadonna G. Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy. Cancer 1986; 58: 1411–1417
   PubMed Web of Science ®Google Scholar
• Tormey DC, Gray G, Abeloff MD. Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: An Eastern Cooperative Oncology Group Trial. J Clin Oncol 1992; 10: 1848–1856
   PubMed Web of Science ®Google Scholar
• Speer JF, Petrovsky VE, Tetsky MW, Wardwell RH. A stochastic numerical model of breast cancer that simulates clinical data. Clinical Res 1984; 44: 4124–4130
   Google Scholar
• Norton L. A Gompertzian model of human breast cancer growth. Cancer Res 1988; 48: 7067–7071
   PubMed Web of Science ®Google Scholar
• Norton L. Implications of kinetic heterogeneity in clinical oncology. Semin Oncol 1985; 12: 231–249
   PubMed Web of Science ®Google Scholar
• Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986; 70: 163–169
   PubMedGoogle Scholar
• Morrow M, Braverman A, Thelmo W. Multimodal therapy for locally advanced breast cancer. Arch Surg 1986; 121: 1291–1296
   PubMed Web of Science ®Google Scholar
• Conte PF, Alama A, Bertelli G. Chemotherapy with estrogenic recruitment and surgery in locally advanced breast cancer: Clinical and cytokinetic results. Int J Cancer 1987; 40: 490–494
   PubMed Web of Science ®Google Scholar
• Swain SM, Sorace RA, Bagley CS. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res, 47: 3889–3894, 10 = 987
   PubMed Web of Science ®Google Scholar
• Hryniuk WM, Figueredo A, Goodyear M. Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol 1987; 14: 3–11, Suppl 4
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981; 304: 10–15
   PubMed Web of Science ®Google Scholar
• Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. Important Advances in Oncology 1988, VT DeVita, Jr, S Hellman, SA Rosenberg. JB Lippincott, Philadelphia 1988; 121–141
   Google Scholar
• Budman D, Wood W, Henderson IC. Initial findings of CALGB 8541: A dose and dose-intensity trial of cyclophosphamide, doxorubicin, and 5-fluorouracil as adjuvant treatment of stage II, note + female breast cancer. Proc Am Soc Clin Oncol 1992; 11: 51
   Google Scholar
• Peters WP, Ross M, Vredenburgh. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132–1143
   PubMed Web of Science ®Google Scholar
• Buzzoni R, Bonadonna G, Vallagussa P, Zambetti M. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol 1991; 9: 2134–40
   PubMed Web of Science ®Google Scholar
• Hudis C, Lebwohl D, Crown J. Feasibility of adjuvant dose-intensive cyclophosphamide with G-CSF after doxorubicin in women with high risk stage II/III resectable breast cancer. Proc Am Soc Clin Oncol 1992; 11: 55
   Google Scholar